Related Experiment Videos
Tissue polypeptide-specific antigen in renal cell carcinoma
European Urology
|January 1, 1996
Summary
Serum tissue polypeptide-specific antigen (TPS) shows potential as a prognostic marker in renal cell carcinoma (RCC). Elevated TPS levels in RCC patients indicate tumor progression and can decrease after successful treatment.
Area of Science:
- Oncology
- Biochemistry
Background:
- Renal cell carcinoma (RCC) is a significant health concern.
- Tissue polypeptide-specific antigen (TPS) is a marker associated with cytokeratin 18.
Purpose of the Study:
- To assess the clinical utility of serum TPS as a prognostic marker in RCC.
- To evaluate TPS expression in normal and cancerous renal tissues and its correlation with disease status and treatment response.
Main Methods:
- Immunohistochemistry was used to determine TPS expression in renal tissues.
- Serum TPS concentrations were measured using a TPS immunoradiometric assay in healthy controls, RCC patients (pre- and post-surgery), and patients receiving immunotherapy.
Main Results:
- TPS is expressed in both normal and cancerous renal epithelial cells.
- Elevated serum TPS levels were observed in locoregional RCC patients, decreasing post-surgery.
- In advanced RCC patients treated with interferon-gamma, persistently high TPS levels correlated with progressive disease, while lower levels indicated response or stable disease.
Conclusions:
- Serum TPS may serve as a valuable prognostic marker in RCC.
- TPS levels potentially reflect the proliferative activity of the tumor, aiding in treatment monitoring.